Palvella Therapeutics, Inc.
151.34USD
-0.9400 (-0.62%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-1.74▼ | $-1.47 | 1 | 6 |
| Next quarter | $-2.09▼ | $-1.76 | 1 | 6 |
| Current year | $-6.37▼ | $-5.57 | 1 | 7 |
| Next year | $-7.5▼ | $-6.68 | 1 | 7 |
Beat in 0 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-1.15 | $-1.52 | -0.37 (-32.0%) |
| 2026-03-31 | $-0.93 | $-1.2 | -0.27 (-29.3%) |
| 2025-12-31 | $-0.91 | $-1.08 | -0.17 (-18.6%) |
| 2025-09-30 | $-0.85 | $-1.03 | -0.18 (-21.3%) |
58 ratings from 17 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Stephens & Co. | Reiterated | Overweight | $220 | May 21, 2026 |
| Chardan Capital | Maintained | Buy | $240 | May 21, 2026 |
| Stephens & Co. | Initiated | Overweight | $220 | May 12, 2026 |
| Chardan Capital | Maintained | Buy | $210 $240 | Mar 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $255 $270 | Mar 24, 2026 |
| Chardan Capital | Maintained | Buy | $210 | Mar 16, 2026 |
| Mizuho | Maintained | Outperform | $205 $250 | Feb 25, 2026 |
| BTIG | Maintained | Buy | $192 $215 | Feb 25, 2026 |
| Chardan Capital | Maintained | Buy | $174 $210 | Feb 24, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $200 $255 | Feb 24, 2026 |
| BTIG | Reiterated | Buy | $192 | Jan 29, 2026 |
| BTIG | Reiterated | Buy | $192 | Jan 16, 2026 |
| Mizuho | Initiated | Outperform | $205 | Jan 7, 2026 |
| Truist Securities | Maintained | Buy | $105 $190 | Dec 16, 2025 |
| Canaccord Genuity | Maintained | Buy | $148 $204 | Dec 16, 2025 |
| TD Cowen | Maintained | Buy | $97 $133 | Dec 16, 2025 |
| Chardan Capital | Maintained | Buy | $110 $174 | Dec 16, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $190 $200 | Dec 15, 2025 |
| BTIG | Maintained | Buy | $167 $192 | Dec 15, 2025 |
| Clear Street | Initiated | Buy | $200 | Dec 5, 2025 |
| BTIG | Initiated | Buy | $167 | Dec 5, 2025 |
| Craig-Hallum | Initiated | Buy | $175 | Dec 4, 2025 |
| Stifel | Maintained | Buy | $87 $145 | Nov 24, 2025 |
| Raymond James | Upgraded from Outperform | Strong Buy | $92 $143 | Nov 19, 2025 |
| Canaccord Genuity | Maintained | Buy | $90 $148 | Nov 13, 2025 |
29 filings from 5 insiders · 9 buy / 7 sell over 6m
Officers and directors of PVLA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KIRITSY CHRISTOPHER PDirector | ExerciseStock Option (Right to Buy) | 313 | — | — | Sep 2, 2026 |
| KIRITSY CHRISTOPHER PDirector | Sell | 313 | $157.00 | $49k | Sep 2, 2026 |
| KIRITSY CHRISTOPHER PDirector | Exercise | 313 | $127.20 | $40k | Sep 2, 2026 |
| GOIN KATHLEENChief Operating Officer | Sell | 4.3k | $151.39 | $655k | Aug 19, 2026 |
| GOIN KATHLEENChief Operating Officer | Exercise | 4.3k | $7.14 | $35k | Aug 19, 2026 |
| GOIN KATHLEENChief Operating Officer | Exercise | 4.3k | $7.14 | $35k | Jul 15, 2026 |
| GOIN KATHLEENChief Operating Officer | Sell | 4.3k | $147.14 | $642k | Jul 15, 2026 |
| GOIN KATHLEENChief Operating Officer | Exercise | 4.3k | $7.14 | $35k | Jun 17, 2026 |
| GOIN KATHLEENChief Operating Officer | Sell | 4.3k | $110.26 | $476k | Jun 17, 2026 |
| KORENBERG MATTHEW EChief Financial Officer | Exercise | 1.0k | $13.60 | $14k | Jun 12, 2026 |
| GOIN KATHLEENChief Operating Officer | Exercise | 4.3k | $7.14 | $35k | May 20, 2026 |
| GOIN KATHLEENChief Operating Officer | Sell | 4.3k | $110.35 | $476k | May 20, 2026 |
| GOIN KATHLEENChief Operating Officer | Exercise | 4.3k | $7.14 | $35k | Apr 15, 2026 |
| GOIN KATHLEENChief Operating Officer | Sell | 4.3k | $125.96 | $547k | Apr 15, 2026 |
| JENKINS GEORGE MDirector | Buy | 445 | $112.30 | $50k | Mar 30, 2026 |
| GOIN KATHLEENChief Operating Officer | Exercise | 4.3k | $7.14 | $35k | Mar 18, 2026 |
| GOIN KATHLEENChief Operating Officer | Sell | 4.3k | $117.56 | $508k | Mar 18, 2026 |
| JENKINS GEORGE MDirector | Buy | 4.0k | $125.00 | $500k | Feb 27, 2026 |
| HERON ELAINE JDirector | Buy | 2.4k | $125.00 | $300k | Feb 27, 2026 |
| GOIN KATHLEENChief Operating Officer | Exercise | 4.3k | $7.14 | $35k | Feb 18, 2026 |
No analyst notes on PVLA yet.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 15 | 0 | 0 | 0 | Buy2.00 |
| 1 mo ago | 0 | 15 | 0 | 0 | 0 | Buy2.00 |
| 2 mo ago | 0 | 15 | 0 | 0 | 0 | Buy2.00 |